Schoenherr has established a new Healthcare & Life Sciences group, jointly led by Corporate/M&A Partner Florian Kusznier and Dispute Resolution Andreas Natterer.
The advisory range of the new Healthcare & Life Sciences group includes pharmaceuticals, medical devices, food, nutritional supplements and animal feed, genetic engineering and chemicals, as well as advice to physicians, other medical professions, nursing and care homes, hospitals and their operators, as well as investors in the health sector.
According to Schoenherr, "the healthcare sector is strongly regulated, but at the same time has a high degree of potential for innovation, which makes it interesting for technological development and investment. Legal advice in this field requires in-depth expertise and experience to deliver high-quality solutions tailored to the specificities of the industry. In Austria and the CEE region, Schoenherr has been successfully advising representatives from the healthcare, life sciences, biotech and pharmaceutical sectors for many years, from individual physicians to international corporations. Most recently, Schoenherr advised Roche on the acquisition of the diabetes app developer mySugr as reported by CEE Legal Matters on July 13, 2017.
"Clients from the healthcare sector benefit from thorough industry and product-specific knowledge from various practice areas," said Florian Kusznier. "Moreover, with its network of international offices, Schoenherr offers excellent geographical coverage for the growing healthcare sector.
"A particular focus of our activities is on regulatory pharmaceutical and food law, where we are already one of the leading law firms in Austria," added Andreas Natterer. "Our aim is to broaden our comprehensive expertise and to further improve the overall advice we provide to clients in the healthcare sector."